Clinical trial · Interventional
TCR-Redirected T Cells Therapy in Patient With HBV Related HCC
NCT03899415CI-TRIAL-00038057unknownPhase 1ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is a single center. single arm, open-label study to determine the safety and clinical benefit of TCR-redirected T cell therapy in patient with HBV related HCC post hepatectomy or radiofrequency ablation.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hepatocellular Carcinoma | Hepatocellular Carcinoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| TCR redirected T cells | Biological | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- TCR-Redirected T Cells
- description
- HBV antigen specific TCR redirected T cells
- interventionNames
- Biological: TCR redirected T cells
Primary outcomes (1)
- measure
- Safety evaluation based in Incidences of adverse events/serious adverse events
- timeFrame
- Up to 1 month after the last infusion
- description
- Review the safety profile of T-Cell Therapy by assessing adverse/serious adverse events reported.
Secondary outcomes (2)
- measure
- Overall Response Rate
- timeFrame
- Start of Treatment until first documented CR or PR, assessed up to 56 treatment weeks (protocol-defined treatment duration is until disease progression, death, or loss to follow up, whichever came first)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 70 Years
Show eligibility criteria text
Inclusion Criteria: 1. Expression of the specific human leukocyte antigen (HLA) class I profile 2. Hepatocellular carcinoma (HCC) with positive test for hepatitis B virus surface antigen (HBsAg) 3. BCLC stage C 4. At least 1 month after surgical intervention or 2 weeks after TACE (may include other type of resection/ablation) No major post-operative complication 5. Laboratory criteria: 1. Liver function: Child A, ALT \< 200 U/L, AST \< 200 U/L, Tbil \< 17.1umol/L 2. Renal Function: Creatinine clearance ≥ 60ml/minute 3. Cardiac Function: No abnormality in cardiac enzyme and ECG 4. Pulmonary Function (Lung): No abnormality in chest X-ray 6. Sexually active subjects must be willing to use an acceptable method of contraception 7. Willing and able to provide written, signed informed consent after the nature of the study has been explained, and prior to any research-related procedures Exclusion Criteria: 1. Subject experiencing acute infection or gastric bleeding within 30 days 2. Mid to late stage cirrhosis, i.e. Child-Pugh Score ≥ 7 3. Known history of testing positive for human immunodeficiency virus (HIV) 4. Other liver complications, including alcoholic liver disease, non-alcoholic autoimmune liver disease, drug induced liver disease 5. Serious systemic conditions, such as mental illness, cerebrovascular disease, coronary heart disease, diabetes, epilepsy 6. Women who are pregnant or breast-feeding 7. History of allergic reaction to blood products or investigational products 8. History of chronic alcoholism or drug abuse/addiction 9. Require systemic medications, such as steroids during the period of study drug administration 10. Exposure to any cell therapy such as, but not limited to NK, CIK, DC, CTL, stem cells therapy 6 months prior to study drug administration 11. Use of any investigational product (IP) or investigational medical device 12. Any condition which could jeopardize the safety of the patient and his/her compliance in the study
References
Publications (1)
- DERIVEDMeng F, Zhao J, Tan AT, Hu W, Wang SY, Jin J, Wu J, Li Y, Shi L, Fu JL, Yu S, Shen Y, Liu L, Luan J, Shi M, Xie Y, Zhou CB, Wong RW, Lu-En W, Koh S, Bertoletti A, Wang T, Zhang JY, Wang FS. Immunotherapy of HBV-related advanced hepatocellular carcinoma with short-term HBV-specific TCR expressed T cells: results of dose escalation, phase I trial. Hepatol Int. 2021 Dec;15(6):1402-1412. doi: 10.1007/s12072-021-10250-2. Epub 2021 Nov 30. PMID 34850325